Pep IQ
← Pep IQ
Substantial and growing. MOTS-c is a 16-amino-acid mitochondrially-encoded peptide (mitochondrial open reading frame of the 12S rRNA type-c, encoded in the MT-RNR1 gene) — distinct from nuclear-encoded peptides because it originates in the mitochondrial genome itself. Mechanism: regulates metabolic homeostasis via AMPK activation and translocates to the nucleus to regulate adaptive gene expression in response to cellular stress. A 2021 study demonstrated that MOTS-c administration significantly enhanced physical performance in young (2 months), middle-aged (12 months), and old (22 months) mice. Late-life initiated intermittent MOTS-c treatment (3× weekly from 23.5 months) increased physical capacity and healthspan in mice. Doses in mouse studies: 15 mg/kg/day daily for 2 weeks, or intermittent 3× weekly long-term.
Community use is limited and protocols are not converged. Typical SubQ doses are 5–10 mg 2–3× weekly extrapolated from mouse mg/kg with allometric scaling, but no human dose-finding has been done. Often run alongside mitochondrial-support stacks (NAD precursors, urolithin A, exercise).
No therapeutic human clinical trials of MOTS-c have been published. The strongest human evidence is correlative: a 2021 study showed endogenous MOTS-c levels significantly increase in human skeletal muscle (11.9-fold) and circulation (1.5-fold) following exercise. MOTS-c serum concentration positively correlates with lower-body muscle strength. Levels associate with longevity in centenarians. Chronic endurance exercise studies in professional athletes have characterised the response curve. These are association studies — they suggest MOTS-c is a biomarker for metabolic and exercise health, but they do not prove that exogenous MOTS-c administration in healthy humans produces the effects seen in mice.
Not approved by any regulatory agency. WADA-flagged: USADA explicitly identifies MOTS-c as a peptide with potential performance-enhancement implications. Sold by research-peptide vendors. No long-term safety data exists in humans.
MOTS-c is encoded by mitochondrial DNA. Published mouse data covers exercise capacity and healthspan. Correlative human evidence links endogenous levels to muscle strength and longevity. No therapeutic human trials have been completed. Community use proceeds without validated dosing, and the compound's behaviour in humans at supraphysiological levels (above what exercise produces) is unknown.
MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c — a mouthful that reflects where it comes from. Unlike virtually every other peptide in this book, MOTS-c is not encoded by nuclear DNA. It is encoded directly by the mitochondrial genome — the small, circular strand of DNA that mitochondria have carried since they were independent bacteria billions of years ago.
It was discovered in 2015 by a research team led by Pinchas Cohen at the University of Southern California, who found a short open reading frame hidden within the 12S ribosomal RNA region of mitochondrial DNA — a region previously thought to contain no protein-coding sequences. This discovery fundamentally changed how scientists think about the mitochondrial genome, which had long been considered a relatively simple system encoding only 13 proteins for energy production.
MOTS-c is found in the blood and in virtually all tissues containing mitochondria. Crucially, its levels decline with age — a pattern that has made it intensely interesting to longevity researchers. It is also one of the most responsive peptides to physical exercise, with skeletal muscle levels rising nearly 12-fold during exercise compared to pre-exercise values.
MOTS-c is frequently described as an "exercise mimetic" — a compound that activates many of the same metabolic pathways triggered by physical exercise. This is not marketing language; it reflects a specific and well-studied mechanism involving AMPK, one of the most important energy-sensing enzymes in the body.
The primary pathway works through the folate-AICAR-AMPK cascade. MOTS-c inhibits the folate cycle and de novo purine biosynthesis, which causes a build-up of AICAR — a molecule that directly activates AMPK. Once AMPK is activated, a cascade of metabolic effects follows that closely mimics what happens during exercise: increased glucose uptake, enhanced fatty acid oxidation, improved insulin sensitivity, and mitochondrial biogenesis.
What distinguishes MOTS-c from many peptides in the longevity space is that it is not foreign to the body — it is something the body already produces, already uses, and already responds to. The question researchers and biohackers are asking is not "does this work?" but rather: can supplementing what the body already makes, as levels decline with age, restore some of what is lost? That is a meaningfully different question than asking whether an entirely synthetic compound does something useful.
The following reflects the current state of evidence — predominantly preclinical, with some early human signals. This is a rapidly evolving area and the picture will look different in five years.